Rongcan Biotech key facts
- Developer of mRNA-based pharmaceutical products designed for nucleic acid-based therapeutics.
- It has raised $13.8M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Anhui Investment Group Holdings, Guangzhou Yuexiu Industrial Investment Fund Management, Hangzhou Huafang Chuangliang Investment Management, Shaanxi Growth Enterprise Guide Fund, Win-Win Capital — 9 tracked in total.
- Status: Privately Held (backing).
Who backs Rongcan Biotech
9- ·Watch Rongcan Biotech: the Monday email on marks, rounds and moves
Rongcan Biotech funding rounds
No funding rounds for Rongcan Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Rongcan Biotech investors
9 investors are on record for Rongcan Biotech, including Anhui Investment Group Holdings, Guangzhou Yuexiu Industrial Investment Fund Management, Hangzhou Huafang Chuangliang Investment Management and Shaanxi Growth Enterprise Guide Fund.
About Rongcan Biotech
Developer of mRNA-based pharmaceutical products designed for nucleic acid-based therapeutics. The company strives to become a whole-industry-chain company that covers from mRNA sequential design and synthesis, and LNP-based delivery systems to finished mRNA-based pharmaceutical products, enabling patients with efficient drug delivery.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Website
- rc-rna.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Rongcan Biotech doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.